Onxeo S.A. announced having received a communication from the European Patent Office (EPO) informing the company of its intent to grant a new patent covering AsiDNA, Onxeo’s first-in-class DNA break repair inhibitor candidate in all countries of the European Union (EU). This new patent significantly strengthens the Company’s intellectual property portfolio by protecting several conjugated nucleic acid molecules including AsiDNA as well as the pharmaceutical compositions and their therapeutic uses, especially for treating cancer, standalone and in combination with a DNA-damaging antitumoral agent (such as radiotherapy, chemotherapy or other tumor DNA damage-inducing agents). This European patent has a term expiring in mid-2031. This term could be further extended to mid-2036 through a supplementary protection certificate (SPC).